October 29, 2020

The Niche

Knoepfler lab stem cell blog

patents

5 min read

What is the “proper” amount of freedom of choice for patients in medicine? What if the treatments in question are experimental and come with their own baggage of associated risks, personal costs, and potential costs to society? More broadly, do patients have a fundamental right to medical choice? These questions seem particularly appropriate today on a number of fronts including Right To Try laws and vaccines as well as emerging stem cell and other biomedical technologies. The recent measles outbreaks including the one sparked at …Read More

1 min read

With more than 250 votes cast, Jennifer Doudna is leading by a decisive margin in a poll asking who deserves the patent for use of CRISPR-Cas9 as a tool. Feng Zhang got only just over half the votes of Doudna. Another take home message from this poll is that a sizable minority–almost one in five– said neither should have a patent on this technology. Geographically the results were fairly consistent across countries, but notably in the UK the top response was, “Neither”. This poll is …Read More

1 min read

The challenge to the WARF/Jamie Thomson patents/IP on human embryonic stem cells (hESC) is at an end. The US Supreme Court declined to hear the case. Earlier, the USPTO had turned down the challenge leading to a winding road in the courts. What do you all think of this stem cell IP challenge and the outcome? The hESC IP includes 3 patents: 5,843,780, 6,200,806, and 7,029,913. For two great stories with helpful background on this development see here and here by David Jensen and Bradley Fikes, respectively. Scripps …Read More

2 min read

The still mysterious BioGatekeeper had challenged Yamanaka’s IPS cell patent claiming that it was obvious. The potential implications were huge given the commercial interest in translating IPS cell technology. For background see here, here, and here. There’s pretty much zero information on BioGatekeeper otherwise. Despite the potential seriousness of this patent challenge, just a few days ago the Patent Trial and Appeal Board (PTAB) denied the challenge so for all intents and purposes BioGatekeeper’s effort is dead. A big hat tip to reader Shinsakan. You …Read More